KIF20A and metastatic malignant neoplasm in the lymph nodes: Additionally, high KIF20A expression was associated with poorer 5-year OS and PFS in both the entire cohort of patients and the subgroups with T3–T4 disease, lymph node metastasis, clinical stage III–IV disease and CCRT subgroups.